Climb Bio, Inc. (CLYM)
| Market Cap | 608.53M +364.8% |
| Revenue (ttm) | n/a |
| Net Income | -59.31M |
| EPS | -0.82 |
| Shares Out | 58.74M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 667,804 |
| Open | 10.76 |
| Previous Close | 10.87 |
| Day's Range | 10.19 - 10.99 |
| 52-Week Range | 1.64 - 18.33 |
| Beta | -0.01 |
| Analysts | Strong Buy |
| Price Target | 28.40 (+174.13%) |
| Earnings Date | Nov 5, 2026 |
About CLYM
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company’s lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for CLYM stock is "Strong Buy." The 12-month stock price target is $28.4, which is an increase of 174.13% from the latest price.
News
Climb Bio management to meet with B. Riley
Meeting to be held in London, England on November 17 hosted by B. Riley.
Climb Bio price target raised to $26 from $20 at Freedom Broker
Freedom Broker raised the firm’s price target on Climb Bio (CLYM) to $26 from $20 and keeps a Buy rating on the shares. Climb Bio reported encouraging early pharmacodynamic data…
Climb Bio Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Budo’s PMN data support dose selection for a potential single-study phase III, while ITP and SLE programs continue to develop. CLYM116 phase II IgAN data are expected in H1 2027, with phase III planned thereafter subject to regulatory alignment; cash runway extends into H2 2028.
Climb Bio price target raised to $27 from $25 at Wedbush
Wedbush raised the firm’s price target on Climb Bio (CLYM) to $27 from $25 and keeps an Outperform rating on the shares. While the Q3 print itself is quiet, the…
Climb Bio files automatic mixed securities shelf
08:31 EST Climb Bio (CLYM) files automatic mixed securities shelf
Climb Bio reports Q3 EPS (19c), consensus (19c)
“We are building significant momentum across our programs, CLYM116 and budoprutug” said Aoife Brennan, President and Chief Executive Officer of Climb Bio (CLYM). “For CLYM116, two independent datasets...
Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates
CLYM116 Phase 1 data in healthy volunteers showed sustained >90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose, supporting every-12-week dosing Initiated dosing in ...
Climb Bio Quarterly report: Q3 2026
Climb Bio has published its Q3 2026 quarterly earnings report on November 5, 2026.
Climb Bio Earnings release: Q3 2026
Climb Bio released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
WELLESLEY HILLS, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, tod...
Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
WELLESLEY HILLS, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, tod...
Climb Bio management to meet with Truist
Analyst Brill holds a dinner meeting with management in Boston on October 26 hosted by Truist.
Climb Bio management to meet with Truist
Analyst Brill holds a dinner meeting with management in Boston on October 26 hosted by Truist.
Climb Bio announces new data for budoprutug
Climb Bio (CLYM) announced new clinical data for budoprutug, its anti-CD19 monoclonal antibody, in two immune-mediated renal diseases, primary membranous nephropathy and minimal change disease, MCD. T...
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anti...
Climb Bio, Mabworks announce additional Phase 1 data for CLYM116/MIL116
Climb Bio (CLYM) announced additional Phase 1 data in healthy volunteers for CLYM116/MIL116, an anti-APRIL monoclonal antibody, in development for IgA nephropathy. These data were presented at the Ame...
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 12 weeks ~33-day half-life NAVIGATE-2 Phase 2 trial enrolling, with initial data ex...
Climb Bio management to meet virtually with Piper Sandler
Virtual Meeting to be held on October 26 hosted by Piper Sandler.
Climb Bio initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of Climb Bio (CLYM) with a Buy rating and $28 price target Climb is a clinical-stage biotech company with two “promising” assets in development for autoimmune…
Climb Bio initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of Climb Bio (CLYM) with a Buy rating and $28 price target
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation
Climb Bio added to ‘Analysts Current Favorites’ at Raymond James
Raymond James added Climb Bio (CLYM) to the firm’s “Analysts Current Favorites” list while removing Tyra Biosciences (TYRA). Climb’s setup for both its lead assets – CLYM116 and budoprutug –…
Climb Bio Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Two lead assets, CLYM116 and budoprutug, are advancing in B-cell mediated diseases with strong clinical data and best-in-class profiles. CLYM116’s Q12-week dosing and sweeper mechanism offer key differentiation in IgAN, while budoprutug targets broader B-cell depletion. Multiple data readouts and pivotal trials are planned, supported by a strong financial position.
Climb Bio Transcript: Wells Fargo 21st Annual Healthcare Conference
Two antibody programs are advancing in immune-mediated diseases, with CLYM116 showing best-in-class 12-week dosing and safety in IgAN, and budoprutug demonstrating strong efficacy in pMN and ITP. Multiple pivotal trials and data readouts are planned through 2025, supported by a strong financial position.
Climb Bio price target raised to $25 from $18 at Oppenheimer
Oppenheimer raised the firm’s price target on Climb Bio (CLYM) to $25 from $18 and keeps an Outperform rating on the shares. The recent CLYM116 reveal illustrates a best-in-class clinical…